DNMT3A low-expression is correlated to poor prognosis in childhood B-ALL and confers resistance to daunorubicin on leukemic cells
Li Weijing, Liu Shuguang, Wang Chanjuan, Cui Lei, Zhao Xiaoxi, Liu Wei, Zhang Ruidong, Li Zhigang
Journal:BMC CANCER
IF:3.8
DOI:10.1186/s12885-023-10724-6
PMID:36934225
Published:2023-03-18
research field:肿瘤学分子生物学血液学
Abstract
Background Little is known about DNMT3A expression and its prognostic significance in childhood B cell acute lymphoblastic leukemia (B-ALL). Methods We determined DNMT3A mRNA expression in 102 children with B-ALL. Correlations with relapse-free survival (RFS) and common clinical characteristics were analyzed. DNMT3A was stably knocked out by CRISPR/Cas9 gene editing technology in Reh and 697 B-ALL cell lines. Cell proliferation activity after treated with daunorubicin (DNR) was determined by CCK8 assay in DNMT3A KO Reh and 697 cell lines. Results DNMT3A expression in B-ALL patients who were in continuous complete remission (CCR) was higher than in those who got relapse ( P = 0.0111). Receiver operating characteristic curve showed prognostic significance of DNMT3A expression ( P = 0.003). Low expression of DNMT3A (≤ 0.197) was significantly correlated with poor RFS ( P < 0.001) in children with B-ALL. Knock-out of DNMT3A in Reh and 697 cell lines significantly increased IC50 of DNR ( P = 0.0201 and 0.0022 respectively), indicating elevated resistance to DNR. Conclusion Low expression of DNMT3A associates with poor prognosis in children with B-ALL. Knock-out of DNMT3A confers resistance to DNR on leukemic cells.
本文使用的Yeasen产品


